Cargando…
Infliximab (Remicade) in the treatment of psoriatic arthritis
Elucidation of the cellular immunopathology and cytokine profile of psoriatic arthritis (PsA), a chronic inflammatory disease associated with psoriasis, has resulted in the development of a number of novel biologic therapies. Among these biologics, tumor necrosis factor-alpha (TNF-α) inhibitors have...
Autor principal: | Mease, Philip |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936360/ https://www.ncbi.nlm.nih.gov/pubmed/18360651 |
Ejemplares similares
-
Remicade(®) (infliximab): 20 years of contributions to science and medicine
por: Melsheimer, Richard, et al.
Publicado: (2019) -
Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016) -
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab)
por: Derzi, Mazin, et al.
Publicado: (2016) -
A descriptive analysis of real-world treatment patterns of innovator (Remicade(®)) and biosimilar infliximab in an infliximab-naïve Turkish population
por: Yazici, Yusuf, et al.
Publicado: (2018) -
Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis
por: Mease, Philip J.
Publicado: (2014)